RECODE · 연구동향생성일 2026-10-31

연구동향

기준 논문: The Effect of Choline Acetyltransferase Genotype on Donepezil Treatment Response in Patients with Alzheimer's Disease

Clin Psychopharmacol Neurosci 13(2):168-173 · 2015 · PMID 26243844

검색 방법

이 논문의 제목과 주제어를 바탕으로 이 논문이 속한 연구 분야를 묻는 질문을 만들어 ReviewFast에 넣어 2026-10-31에 검색했습니다. ReviewFast가 PubMed를 검색하고, AI 모델(Jev)이 제목과 초록을 읽어 질문과의 관련도를 매긴 뒤 주제별로 묶었습니다.

140편 검색→133편 판독→56편 선별 (관련도 0.5 이상)

질문과 PubMed 검색식 보기질문: Pharmacogenetics of donepezil response in Alzheimer disease (donepezil[tiab] OR donepezil[MeSH Terms]) AND (pharmacogenetic*[tiab] OR pharmacogenomic*[tiab] OR polymorphism*[tiab] OR genotype*[tiab] OR CYP2D6[tiab] OR APOE[tiab]) AND (Alzheimer*[tiab] OR Alzheimer Disease[MeSH Terms])

출판 연도

2002: 2편220022004: 1편12005: 2편220052006: 3편32007: 1편12008: 1편12009: 2편22010: 2편220102011: 6편62012: 1편12013: 3편32014: 5편52015: 5편520152016: 3편32017: 2편22018: 1편12019: 3편32020: 5편520202021: 4편42022: 1편12024: 1편12025: 2편22025

선별된 56편의 출판 연도. 검색일(2026-10-31) 기준이며, 그 이후 논문은 들어 있지 않습니다.

주제별 논문

주제 이름은 ReviewFast가 초록의 단어로 자동으로 붙인 것입니다. 왼쪽 숫자는 관련도(0–1)입니다. RECODE 는 우리 연구팀 논문입니다.

01cyp2d6 · polymorphisms25편

  1. 0.96

    Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease

    Lu J, Wan L, Zhong Y et al. · Journal of pharmacological sciences · 2015

  2. 0.96

    Role of cytochrome P4502D6 functional polymorphisms in the efficacy of donepezil in patients with Alzheimer's disease

    Seripa D, Bizzarro A, Pilotto A et al. · Pharmacogenetics and genomics · 2011

  3. 0.96

    Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease

    Zhong Y, Zheng X, Miao Y et al. · The American journal of the medical sciences · 2013

  4. 0.95

    Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease

    Pilotto A, Franceschi M, D'Onofrio G et al. · Neurology · 2009

  5. 0.95

    Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients

    Albani D, Martinelli Boneschi F, Biella G et al. · Journal of Alzheimer's disease : JAD · 2012

  6. 0.95

    Association of CHAT Gene Polymorphism rs3793790 and rs2177370 with Donepezil Response and the Risk of Alzheimer's Disease Continuum

    Sun H, Lv C, Zhang X et al. · Clinical interventions in aging · 2024

  7. 0.95

    Influence of CYP2D6, CYP3A5, ABCB1, APOE polymorphisms and nongenetic factors on donepezil treatment in patients with Alzheimer's disease and vascular dementia

    Yaowaluk T, Senanarong V, Limwongse C et al. · Pharmacogenomics and personalized medicine · 2019

  8. 0.95

    Impact of the CYP2D6 single nucleotide polymorphism on the concentration of and therapeutic response to donepezil in mild-to-moderate Alzheimer's disease

    Chou PS, Huang LC, Hour TC et al. · Journal of the Formosan Medical Association = Taiwan yi zhi · 2022

  9. 0.94

    Influence of rs1080985 single nucleotide polymorphism of the CYP2D6 gene on response to treatment with donepezil in patients with alzheimer's disease

    Klimkowicz-Mrowiec A, Wolkow P, Sado M et al. · Neuropsychiatric disease and treatment · 2013

  10. 0.94

    The impact of CYP2D6 on donepezil concentration and its lack of effect on the treatment response and adverse effect in Korean patients with Alzheimer's disease

    Kim TE, Bae JW, Hong S et al. · The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025

  11. 0.94

    Influence of the rs1080985 Single Nucleotide Polymorphism of the CYP2D6 Gene and APOE Polymorphism on the Response to Donepezil Treatment in Patients with Alzheimer's Disease in China

    Liu M, Zhang Y, Huo YR et al. · Dementia and geriatric cognitive disorders extra · 2014

  12. 0.94

    Association between ABCA1 gene polymorphisms and the therapeutic response to donepezil therapy in Han Chinese patients with Alzheimer's disease

    Lu J, Fu J, Zhong Y et al. · Brain research bulletin · 2018

  13. 0.93

    Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?

    Magliulo L, Dahl ML, Lombardi G et al. · European journal of clinical pharmacology · 2011

  14. 0.93

    Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to Drug Plasma Concentration and CYP2D6 and APOE Genetic Polymorphisms

    Miranda LFJR, Gomes KB, Tito PAL et al. · Journal of Alzheimer's disease : JAD · 2017

  15. 0.93

    Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients

    Varsaldi F, Miglio G, Scordo MG et al. · European journal of clinical pharmacology · 2006

  16. 0.93

    The roles of apolipoprotein E3 and CYP2D6 (rs1065852) gene polymorphisms in the predictability of responses to individualized therapy with donepezil in Han Chinese patients with Alzheimer's disease

    Lu J, Fu J, Zhong Y et al. · Neuroscience letters · 2016

  17. 0.91

    Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease

    Ma SL, Tang NLS, Wat KHY et al. · American journal of Alzheimer's disease and other dementias · 2019

  18. 0.88

    Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil

    Ortner M, Stange M, Schneider H et al. · Drug design, development and therapy · 2020

  19. 0.88

    Donepezil plasma concentrations, CYP2D6 and CYP3A4 phenotypes, and cognitive outcome in Alzheimer's disease

    Coin A, Pamio MV, Alexopoulos C et al. · European journal of clinical pharmacology · 2016

  20. 0.81

    Serum Concentrations of Cholinesterase Inhibitors in Patients With Alzheimer's Dementia Are Frequently Below the Recommended Levels

    Ortner M, Stange M, Schneider H et al. · Frontiers in pharmacology · 2020

  21. 0.80

    Impact of CYP2D6, CYP3A5, and ABCB1 Polymorphisms on Plasma Concentrations of Donepezil and Its Metabolite in Patients With Alzheimer Disease

    Kagawa Y, Yamamoto Y, Ueno A et al. · Therapeutic drug monitoring · 2021

  22. 0.78

    Impact of Plasma Donepezil Concentration on Behavioral and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease

    Kagawa Y, Yamamoto Y, Ueno A et al. · Dementia and geriatric cognitive disorders extra · 2021

  23. 0.74

    Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease

    Sonali N, Tripathi M, Sagar R et al. · Dementia and geriatric cognitive disorders · 2014

  24. 0.71

    Safety and Efficacy of Donepezil 10 mg/day in Patients with Mild to Moderate Alzheimer's Disease

    Jia J, Wei C, Chen W et al. · Journal of Alzheimer's disease : JAD · 2020

  25. 0.59

    Association Between Peripheral Adiponectin and Lipids Levels and the Therapeutic Response to Donepezil Treatment in Han Chinese Patients With Alzheimer's Disease

    Wan L, Lu J, Huang J et al. · Frontiers in aging neuroscience · 2020

02daily living · randomized13편

  1. 0.95

    Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease

    Scacchi R, Gambina G, Broggio E et al. · International journal of geriatric psychiatry · 2014

  2. 0.93

    Are cytochrome P4502D6 and apolipoprotein E genotypes associated with long-term cognitive and functional changes in patients treated with donepezil?

    Pamio MV, Trevisan C, Pigozzo S et al. · Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society · 2020

  3. 0.93

    Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease

    Rigaud AS, Traykov L, Latour F et al. · Pharmacogenetics · 2002

  4. 0.90

    APOE-varepsilon4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease

    Waring JF, Tang Q, Robieson WZ et al. · Journal of Alzheimer's disease : JAD · 2015

  5. 0.88

    CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer's disease

    Weng PH, Chen JH, Chen TF et al. · PloS one · 2013

  6. 0.84

    Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease

    Blesa R, Bullock R, He Y et al. · Pharmacogenetics and genomics · 2006

  7. 0.83

    Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study

    Miranda LFJR, Gomes KB, Silveira JN et al. · Journal of Alzheimer's disease : JAD · 2015

  8. 0.80

    Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study

    Santoro A, Siviero P, Minicuci N et al. · CNS drugs · 2010

  9. 0.80

    Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease

    Bullock R, Bergman H, Touchon J et al. · Current medical research and opinion · 2006

  10. 0.77

    The effect of APOE epsilon4 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging

    Wang L, Day J, Roe CM et al. · Alzheimer disease and associated disorders · 2014

  11. 0.62

    Predictors of long-term cognitive outcome in Alzheimer's disease

    Wattmo C, Wallin AK, Londos E et al. · Alzheimer's research & therapy · 2011

  12. 0.53

    Early-start vs delayed-start donepezil against cognitive decline in Parkinson disease: a randomized clinical trial

    Sawada H, Oeda T, Kohsaka M et al. · Expert opinion on pharmacotherapy · 2021

  13. 0.50

    Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period

    Bullock R, Touchon J, Bergman H et al. · Current medical research and opinion · 2005

03genes · factors9편

  1. 0.93

    BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors

    Chianella C, Gragnaniello D, Maisano Delser P et al. · European journal of clinical pharmacology · 2011

  2. 0.90

    Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine

    Scacchi R, Gambina G, Moretto G et al. · American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2009

  3. 0.88

    Paraoxonase 1 gene polymorphisms do not influence the response to treatment in Alzheimer's disease

    Klimkowicz-Mrowiec A, Marona M, Spisak K et al. · Dementia and geriatric cognitive disorders · 2011

  4. 0.85

    Butyrylcholinesterase K and Apolipoprotein E-varepsilon4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects

    De Beaumont L, Pelleieux S, Lamarre-Theroux L et al. · Journal of Alzheimer's disease : JAD · 2016

  5. 0.80

    Variants in Neurotransmitter-Related Genes Are Associated with Alzheimer's Disease Risk and Cognitive Functioning but Not Short-Term Treatment Response

    Zuniga-Santamaria T, Perez-Aldana BE, Fricke-Galindo I et al. · Neurology international · 2025

  6. 0.63

    Association between human paraoxonase 2 protein and efficacy of acetylcholinesterase inhibiting drugs used against Alzheimer's disease

    Parween F, Hossain MS, Singh KP et al. · PloS one · 2021

  7. 0.63

    Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer's disease pharmacogenetics

    Cacabelos R, Llovo R, Fraile C et al. · Current Alzheimer research · 2007

  8. 0.54

    Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease

    Russo P, Kisialiou A, Moroni R et al. · Current drug targets · 2017

  9. 0.53

    Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer's Disease-Could BCHE Genotyping Be Helpful in Alzheimer's Therapy?

    Jasiecki J, Wasag B · Biomolecules · 2019

04cognitive · sex7편

  1. 0.95

    The Effect of Choline Acetyltransferase Genotype on Donepezil Treatment Response in Patients with Alzheimer's Disease 이 논문

    Lee KU, Lee JH, Lee DY et al. · Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2015

  2. 0.94

    Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease

    Bizzarro A, Marra C, Acciarri A et al. · Dementia and geriatric cognitive disorders · 2005

  3. 0.93

    Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease

    Choi SH, Kim SY, Na HR et al. · Dementia and geriatric cognitive disorders · 2008

  4. 0.88

    FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease

    Paroni G, Seripa D, Fontana A et al. · Clinical interventions in aging · 2014

  5. 0.81

    Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: relating to changes attributable to differences in apolipoprotein E phenotype

    Kanaya K, Abe S, Sakai M et al. · Geriatrics & gerontology international · 2010

  6. 0.67

    Plasma concentration of donepezil to the therapeutic response of Alzheimer's disease in Taiwanese

    Yang YH, Wu SL, Chou MC et al. · Journal of Alzheimer's disease : JAD · 2011

  7. 0.64

    Neuropsychological Evaluation and Cerebral Blood Flow Effects of Apolipoprotein E4 in Alzheimer's Disease Patients after One Year of Treatment: An Exploratory Study

    Suwa A, Nishida K, Utsunomiya K et al. · Dementia and geriatric cognitive disorders extra · 2015

05molecular · binding2편

  1. 0.91

    ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model

    Borroni B, Colciaghi F, Pastorino L et al. · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2002

  2. 0.76

    Functional screening of drug target genes: m1 muscarinic acetylcholine receptor phenotypes in degenerative dementias

    Weiner DM, Goodman MW, Colpitts TM et al. · American journal of pharmacogenomics : genomics-related research in drug development and clinical practice · 2004